Acquired resistance to tyrosine kinase inhibitors (TKIs) is the major obstacle to improve
clinical efficacy in cancer patients. The epithelial-stromal interaction in tumor …

Abstract Anlotinib (AL3818), a novel multi-targeted receptor tyrosine kinase inhibitor, has
recently been proven to be an antitumour drug. This study aimed to explore the antitumour …

Rationale: The sustained and severe endoplasmic reticulum (ER) stress in cancer cells may
contribute to apoptotic cell death, thus representing a potential target for cancer therapy …

For gastric cancer (GC) control, metastasis and chemoresistance are the major challenges,
accompanied with various stresses. Ataxin-2-like (ATXN2L) was discovered as a novel …

Background Anlotinib is a highly potent multi-target tyrosine kinase inhibitor, with very good
anti-tumor activity against a variety of solid tumors. However, its effect on colorectal cancer …

Erlotinib, an EGFR tyrosine kinase inhibitor, is used for treating patients with cancer
exhibiting EGFR overexpression or mutation. However, the response rate of erlotinib is low …

Background Chemoresistance is a main obstacle in gastric cancer (GC) treatment, but its
molecular mechanism still needs to be elucidated. Here, we aim to reveal the underlying …

Background Fibroblast growth factor receptor 1 (FGFR1) is frequently dysregulated in
various tumors. FGFR inhibitors have shown promising therapeutic value in several …

Aim Despite the impressive efficacy of crizotinib for the treatment of ALK-positive non-small
cell lung cancer, patients invariably develop therapeutic resistance. Suppression of the IGF …

Introduction Acquired cancer therapy resistance evolves under selection pressure of
immune surveillance and favors mechanisms that promote drug resistance through cell …